Home / Peptides / Epitalon: Status, Evidence and What Is Still Unknown
Epitalon: Status, Evidence and What Is Still Unknown
Epitalon is not FDA-approved for any use. What HHS's policy covers, what FDA reviewed, why life-span findings come from mice, and a theoretical concern.
On this page
Quick facts
Fact sheet
- U.S. status
- Strongest evidence
- Limited human data
- Status verified
Epitalon is marketed around longevity. FDA reviewed it for a different use, insomnia, and found no clinical data on its safety. This guide sets out what is approved, what HHS’s interim policy covers, and what has and has not been tested in people.
Key takeaways
- Epitalon is not FDA-approved for any use.
- HHS’s October 2026 interim policy covers certain compounded epitalon acetate given by injection in intermittent courses, under conditions. That is enforcement discretion, not FDA approval.
- We found no adequately powered randomized trial in people; life-span findings come from mice.
- FDA reviewed epitalon only for insomnia. It did not evaluate longevity, and it found no studies in patients with insomnia.
- FDA staff raised a theoretical concern that long-term telomere lengthening could allow cells to become cancerous. No such harm has been observed in people, and it has not been ruled out.
- The one registered study, NCT07888595, is not an efficacy trial.
Is epitalon FDA-approved?
No. Epitalon is not FDA-approved for any use. A search of Drugs@FDA on Nov. 7, 2026 found no product listed as epitalon or epithalon; that search shows approved products, not pending applications. FDA also did not find it in the European or Japanese pharmacopeias or in the national registries it consulted (FDA).
What does HHS’s October 2026 policy cover?
HHS’s October 2026 interim policy covers certain compounded epitalon acetate given by injection in intermittent courses, under conditions. That is enforcement discretion, not FDA approval. As we read the policy:
- It covers epitalon acetate, subcutaneous or intramuscular, “dispensed in intermittent courses,” as a single active ingredient, under the policy’s ten conditions.
- It does not cover oral use or the free-base form.
- It does not add epitalon to FDA’s compounding lists. We did not find it in FDA’s 503A categories list.
FDA’s drug center proposed in July 2026 not to list epitalon. The advisory committee voted 7–4–1 in favor of listing it, according to a law-firm account (secondary source). FDA’s page on substances that may present significant safety risks lists epitalon among nominations that were withdrawn, with a concern about immunogenicity and impurities. For how these rules fit together, see 503A compounding of peptides.
What did FDA review?
FDA evaluated epitalon only for insomnia, not for longevity (FDA briefing). It found no randomized trial on a clinical outcome for insomnia, and it said there is no clinical data to support the safety of epitalon.
What studies in people exist?
We found no adequately powered randomized trial in people. A 2026 review reaches the same conclusion.
| Type | What exists | What it does not show |
|---|---|---|
| Randomized trial on a clinical outcome | None identified by FDA for insomnia | n/a |
| Marker study | Ivko 2021: 75 healthy women aged 40 to 50 working night shifts; the 40 with low melatonin-metabolite levels were given placebo or epitalon under the tongue for 20 days (20 vs 20). A urinary metabolite of melatonin rose (as described by FDA) | It did not measure sleep. Blinding was unclear, and there are no safety data |
| Abstract in older adults | Korkushko 2007: reported “no side effects,” without the route, dose, duration or number of people | Cannot be assessed from the abstract |
| Older abstract, retinal disease | A 2002 abstract in retinitis pigmentosa reports a “positive clinical effect in 90% of the cases” | The abstract does not describe a control group |
What about the mouse studies?
Life-span findings come from mice. Research from 2001 to 2003, as described by FDA, found that mice given epitalon intermittently had fewer or smaller spontaneous tumors and lived longer (FDA). Results in mice do not carry over reliably to people.
What is the telomere concern?
Epitalon is marketed for its effect on telomeres, the ends of chromosomes. In lab experiments FDA describes it as increasing telomerase and lengthening telomeres. FDA staff raised a theoretical concern that long-term telomere lengthening could allow cells to become cancerous: continuous exposure could let cells avoid senescence. It is a theoretical concern, not a harm that has been observed, and the cancer-causing potential of continued use is unknown (FDA).
A 2025 laboratory study found that epitalon lengthened telomeres in human cells, including breast cancer cell lines. That is a cell experiment, not a finding in people, and we cite it only because it bears on the concern FDA raised. How lengthening relates to sleep or to human aging is unknown.
Is there a registered clinical trial?
One record, NCT07888595, posted on Oct. 22, 2026. It is an early phase 1 study with a single arm, open-label and without a control group, with 48 participants, listed as enrolling by invitation, from a private institute. It measures “biological age” with aging clocks. It has no results, and it is not an efficacy trial, so it is not evidence that epitalon works (ClinicalTrials.gov search).
Where do HHS and FDA disagree?
We present both and do not choose.
| Question | HHS (policy) | FDA (briefing, slides) |
|---|---|---|
| Safety | CDER’s concerns are “mechanistic rather than based on observed harm”; a controlled human exposure “reported no side effects” | Found no clinical data on safety; the exposure study did not report safety |
| Historical use | Describes it as quantified | FDA said the extent of its use in compounding is unclear; HHS’s data are not published in the text we read |
| Route | Covers subcutaneous and intramuscular | Found no studies in patients with insomnia, particularly by the proposed subcutaneous route |
Both can be true: no observed harm is not proof of safety.
What are the risks?
- No clinical safety data, according to FDA.
- The theoretical cancer concern above.
- Immune reactions. FDA names a risk with the injected route, made worse by aggregation and impurities.
- No reports is not reassurance. FDA’s adverse event system had no reports for epitalon, and FDA cautions that this does not imply the substance is without risk.
Which claims are not supported?
- Claims that epitalon lengthens life or turns back biological age. The life-span findings are from mice, and the registered study measures a marker without a control group.
- “Lengthening telomeres is good for you.” FDA sees it as a possible risk.
- “It improves sleep.” The one marker study did not measure sleep.
- “FDA approved it” or “HHS approved it.” Neither did. The policy is enforcement discretion.
What should you ask your doctor?
- What is behind the concern that makes me interested in epitalon (sleep, aging, a health condition), and what evidence-based options exist?
- If it is suggested, what human evidence supports it for my goal, given that none has been found?
- Is it a compounded product made under a patient-specific prescription, who made it, and does it contain one active ingredient?
- Is there a personal or family history of cancer I should mention?
We do not give doses, cycles or preparation instructions, and we do not recommend sellers. For epitalon next to other peptides marketed for aging, see our guide to peptides for longevity.
Frequently asked questions
Is epitalon FDA-approved?
No. Epitalon is not FDA-approved for any use.
Does epitalon help people live longer?
We found no adequately powered randomized trial in people; life-span findings come from mice.
Is epitalon covered by the HHS policy?
HHS’s October 2026 interim policy covers certain compounded epitalon acetate given by injection in intermittent courses, under conditions. That is enforcement discretion, not FDA approval.
Does epitalon cause cancer?
We found no evidence in people either way. FDA staff raised a theoretical concern that long-term telomere lengthening could allow cells to become cancerous. That risk has not been observed or ruled out in humans.
Is there a clinical trial of epitalon?
One study is registered, NCT07888595. It is a single-arm, open-label early phase 1 study measuring “biological age,” and it is not an efficacy trial.
From Best Peptides Today
Sources we checked
- FDA presentations to the Pharmacy Compounding Advisory Committee on epitalon (July 24, 2026)FDA. Accessed .
- FDA briefing document on epitalonFDA. Accessed .
- FDA CDER proposal on seven peptides (July 2026)FDA. Accessed .
- FDA: bulk drug substances that may present significant safety risks (Category 2)FDA. Accessed .
- FDA: bulk drug substances nominated under section 503A, by category (updated May 14, 2026)FDA. Accessed .
- Drugs@FDA (searched Nov. 7, 2026; no product listed as epitalon or epithalon)FDA. Accessed .
- Federal Register: HHS enforcement discretion policy on 503A peptide compounding (Oct. 30, 2026)Other. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- McDermott+: PCAC votes on peptides (secondary source)Other. Accessed .
- 2026 review of peptide supplements and epitalon (PubMed)PubMed. Accessed .
- Epitalon study in retinitis pigmentosa, 2002 (PubMed)PubMed. Accessed .
- Epitalon and telomere length in human cells, 2025 (PubMed)PubMed. Accessed .
- ClinicalTrials.gov search for epitalon (searched Nov. 7, 2026)ClinicalTrials.gov. Accessed .
- ClinicalTrials.gov NCT07888595 (epitalon, early phase 1, single arm)ClinicalTrials.gov. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.